Novel drug approvals vs Cardiometabolic RNA and next-generation lipid drug trial starts in United States

In 2025, novel drug approvals in United States stood at 46, against 26 for cardiometabolic RNA and next-generation lipid drug trial starts.

Change the pair

Compare different indicators

The series

Over time

United States, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Novel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts

Unit: count · 8 observations

2 series · one axis
Novel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts: United StatesNovel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts. 2 indicators on one axis: Novel drug approvals, Cardiometabolic RNA and next-generation lipid drug trial starts. 8 observations from 2020 to 2025, ranging from 6 to 50. Latest values: Novel drug approvals 46 (2025); Cardiometabolic RNA and next-generation lipid drug trial starts 26 (2025). 0 10 20 30 40 50 2020 2021 2022 2023 2024 2025 46 26 Novel drug approvals Cardiometabolic RNA and next-generation lipid drug trial starts
Novel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts: United StatesNovel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts. 2 indicators on one axis: Novel drug approvals, Cardiometabolic RNA and next-generation lipid drug trial starts. 8 observations from 2020 to 2025, ranging from 6 to 50. Latest values: Novel drug approvals 46 (2025); Cardiometabolic RNA and next-generation lipid drug trial starts 26 (2025). 0 20 40 60 2020 2021 2022 2023 2024 2025 46 26 Novel drug approvals Cardiometabolic RNA and next-generation lipid drug trial starts
Novel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts: United StatesNovel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts. 2 indicators on one axis: Novel drug approvals, Cardiometabolic RNA and next-generation lipid drug trial starts. 8 observations from 2020 to 2025, ranging from 6 to 50. Latest values: Novel drug approvals 46 (2025); Cardiometabolic RNA and next-generation lipid drug trial starts 26 (2025). 0 20 40 60 2020 2021 2022 2023 2024 2025 46 26 Novel drug approvals Cardiometabolic RNA and next-generation lipid drug trial starts
View the underlying data
Novel drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts: United States
Indicator Period Type Value
Novel drug approvals 2025 Actual 46
Novel drug approvals 2024 Actual 50
Cardiometabolic RNA and next-generation lipid drug trial starts 2025 Actual 26
Cardiometabolic RNA and next-generation lipid drug trial starts 2024 Actual 35
Cardiometabolic RNA and next-generation lipid drug trial starts 2023 Actual 13
Cardiometabolic RNA and next-generation lipid drug trial starts 2022 Actual 25
Cardiometabolic RNA and next-generation lipid drug trial starts 2021 Actual 22
Cardiometabolic RNA and next-generation lipid drug trial starts 2020 Actual 6

Shared periods

Side by side

2 periods are published for both series in United States as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Novel drug approvals Cardiometabolic RNA and next-generation lipid drug trial starts
2024 50 FDA 35 ClinicalTrials.gov
2025 46 FDA 26 ClinicalTrials.gov

Provenance

Where these numbers come from

Novel drug approvals

Total number of novel drugs approved for the first time by a regulatory authority within a calendar year.

2 observations charted in United States · source organisations: FDA

Cardiometabolic RNA and next-generation lipid drug trial starts

Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in United States · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related